These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
41 related articles for article (PubMed ID: 11918946)
21. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083 [TBL] [Abstract][Full Text] [Related]
22. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786 [TBL] [Abstract][Full Text] [Related]
23. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800 [TBL] [Abstract][Full Text] [Related]
24. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Iwamoto FM; Schwartz J; Pandit-Taskar N; Peak S; Divgi CR; Zelenetz AD; Humm J; Abrey LE Cancer; 2007 Dec; 110(11):2528-34. PubMed ID: 17932895 [TBL] [Abstract][Full Text] [Related]
25. Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders? Agazzi A; Rocca P; Laszlo D; Bodei L; Grana C; Martinelli G; Paganelli G Eur J Haematol; 2005 May; 74(5):450-1. PubMed ID: 15813923 [No Abstract] [Full Text] [Related]
26. Erratum for 'Presidential address: systemic radiotherapy--the new frontier' by S. Order. Vriesendorp HM Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1676. PubMed ID: 1938579 [No Abstract] [Full Text] [Related]
27. Editorial: "right place, wrong place": extravasation of therapeutic drug for molecular targeted radiotherapy. Denardo GL Cancer Biother Radiopharm; 2006 Apr; 21(2):85-7. PubMed ID: 16706628 [No Abstract] [Full Text] [Related]
31. 90Y-DOTATOC and nephrotoxicity. Otte A; Cybulla M; Weiner SM Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1543. PubMed ID: 12537003 [No Abstract] [Full Text] [Related]
32. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? Konijnenberg MW Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958 [TBL] [Abstract][Full Text] [Related]
33. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Behr TM; Béhé M; Kluge G; Gotthardt M; Schipper ML; Gratz S; Arnold R; Becker W; Goldenberg DM Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):277-9. PubMed ID: 11926391 [No Abstract] [Full Text] [Related]
34. Kidney failure after treatment with 90Y-DOTATOC. Schumacher T; Waldherr C; Mueller-Brand J; Maecke H Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):435. PubMed ID: 12002721 [No Abstract] [Full Text] [Related]